The NSAID Reality

Nonsteroidal anti-inflammatory drugs are widely used for back pain, knee osteoarthritis, and soft tissue injury. They can provide meaningful short-term relief.
But chronic use carries cumulative concerns:

• Gastrointestinal irritation
• Cardiovascular risk
• Renal stress
• Dose escalation
  

For patients with hypertension, cardiovascular disease, or kidney impairment, long-term NSAID exposure requires careful monitoring.
Yet in many cases, NSAIDs remain the default baseline therapy.
The issue is not that NSAIDs are ineffective. The issue is that they are often used continuously for conditions that are themselves chronic.

The Opioid Conversation

Opioids are typically reserved for more severe pain, but history has shown how quickly short-term prescriptions can evolve into long-term dependence.
Even when prescribed responsibly, opioids:

• Alter central pain perception
• Carry risk of tolerance
• Introduce dependence potential
• Impact cognition and daily function
  

For chronic musculoskeletal pain — especially non-malignant pain — most clinicians now prioritize alternatives whenever possible.
The challenge is that alternatives must be consistent and effective enough to serve as a true foundation.

Systemic vs Local Therapy

Opioids and NSAIDs circulate throughout the body. They influence pain signaling at multiple sites — not only where discomfort is located.
Localized therapy operates differently.
By applying modulation directly to the site of pain, a wearable bioelectric device interacts with the tissue environment without systemic distribution.
This distinction is critical.
When treatment remains localized:

• Liver metabolism is unaffected
• Renal filtration is unaffected
• Gastrointestinal mucosa is unaffected
• Central cognition is unaffected
  

For patients seeking to reduce systemic exposure, this matters.

Consistency Reduces Escalation

Escalation in pain management often follows a predictable pattern:
Mild discomfort → intermittent NSAIDs → daily NSAIDs → stronger medication → procedural consideration.
When the baseline environment remains unstable, symptom spikes drive reactive decisions.
Continuous, drug-free therapy may provide a stabilizing layer. If daily discomfort is moderated consistently, patients may be less likely to increase medication frequency.
Medication becomes supplemental rather than foundational.
That shift can be meaningful over years.

Integrating Non-Drug Modalities Early

Non-drug therapy is often introduced late — after medications have already become routine.
A more structured approach introduces localized therapy earlier in the care continuum.
This allows:

• Lower medication reliance from the outset
• Reduced cumulative systemic exposure
• Greater patient confidence in movement
• More predictable symptom control
  

The earlier the foundation is built, the less likely escalation becomes.

Patient Autonomy and Control

Chronic pain affects more than physiology. It affects mood, sleep, productivity, and confidence.
When relief depends entirely on medication timing, patients often feel reactive.
Wearable, continuous therapy introduces autonomy. The device can operate during daily activity, work, travel, and sleep.
That predictability can restore a sense of control — a factor that meaningfully influences long-term outcomes.

A Balanced Perspective

Non-drug therapy is not a cure-all.
Some patients will still require medication. Some conditions require intervention beyond conservative care.
But expanding the foundation of care changes the conversation.
Instead of asking, “What stronger medication comes next?” the question becomes, “How can we stabilize the local environment while minimizing systemic exposure?”
That reframing is central to modern pain management.
In the next article, we turn to access — specifically, how non-drug, wearable therapy fits into broader public health initiatives, including programs designed to expand musculoskeletal care in underserved communities.